Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury PR Newswire NEW YORK...
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis PR Newswire NEW YORK, June...
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery PR...
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing PR Newswire NEW YORK, April 24, 2024 NEW YORK...
Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics PR Newswire NEW...
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing PR Newswire NEW YORK, April 3, 2024 Common stock will begin trading on...
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on...
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's PR...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.